Preclinical development of MGO Manuka Honey microemulsion for blepharitis management.

ResearchSpace Repository

Show simple item record Craig, Jennifer en Rupenthal, Ilva en Seyfoddin, Ali en Cheung, Isabella MY en Uy, Benedict en Wang, Michael en Watters, Grant A en Swift, Simon en 2018-11-18T23:21:24Z en 2017-01 en
dc.identifier.citation BMJ open ophthalmology 1(1):e000065 Jan 201 en
dc.identifier.issn 2397-3269 en
dc.identifier.uri en
dc.description.abstract To evaluate the in vitro antimicrobial effects of cyclodextrin-complexed and uncomplexed Manuka honey on bacteria commonly associated with blepharitis, and in vivo rabbit eye tolerability of a cyclodextrin-complexed methylglyoxal (MGO) Manuka Honey microemulsion (MHME).In vitro phase: Bacterial growth inhibition was assessed by area under the growth curve (AUC) for Staphylococcus aureus, and the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for S. aureus, Staphylococcus epidermidis and Pseudomonas aeruginosa with cyclodextrin-complexed and uncomplexed Manuka honey were determined. In vivo phase: Six rabbits were administered 20 µL of MHME (at 1:10 dilution) to the right eye (treated) and 20 µL of saline to the left eye (control) daily, for 5 days. Tear evaporation, production, osmolarity, lipid layer, conjunctival hyperaemia and fluorescein staining were assessed daily, before and 15 min after instillation.In vitro phase: The relative AUC for cyclodextrin-complexed Manuka honey was lower than that of uncomplexed honey at both 250 and 550 mg/kg of MGO (both p <0.05). Cyclodextrin-complexed honey had lower MIC and MBC than uncomplexed honey for both S. aureus and S. epidermidis, but not P. aeruginosa. In vivo phase: No significant changes were observed in the parameters assessed in either treated or control eyes (all p >0.05).Overall, antimicrobial potency of cyclodextrin-complexed Manuka honey was greater than uncomplexed honey. No significant immediate or cumulative adverse effects were observed with MHME application on rabbit eyes, supporting future conduct of clinical safety and tolerability trials in human subjects. en
dc.format.medium Electronic-eCollection en
dc.language eng en
dc.relation.ispartofseries BMJ open ophthalmology en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri en
dc.rights.uri en
dc.title Preclinical development of MGO Manuka Honey microemulsion for blepharitis management. en
dc.type Journal Article en
dc.identifier.doi 10.1136/bmjophth-2016-000065 en
pubs.issue 1 en
pubs.begin-page e000065 en
pubs.volume 1 en
dc.rights.holder Copyright: The authors en
dc.identifier.pmid 29354709 en
pubs.publication-status Published en
dc.rights.accessrights en
pubs.subtype other en
pubs.subtype Journal Article en
pubs.elements-id 709617 en Medical and Health Sciences en Medical Sciences en Molecular Medicine en School of Medicine en Ophthalmology Department en
dc.identifier.eissn 2397-3269 en
pubs.record-created-at-source-date 2018-01-23 en
pubs.dimensions-id 29354709 en

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record Except where otherwise noted, this item's license is described as


Search ResearchSpace

Advanced Search